In a decline from its 89 approvals in 2022, the European Medicines Agency (EMA) recommended marketing authorizations for 77 human drugs in 2023, including 39 new active substances, 17 orphan drugs, 14 generics, and eight biosimilars, according to the agency’s annual report.
Source: Drug Industry Daily